帕金森病患者的骨折发生率与骨质疏松治疗:一项基于人群的队列研究
该研究利用加拿大安大略省2008年1月至2023年12月的行政数据,纳入28,119例65岁以上新诊断帕金森病患者,描述诊断后1年内的骨折发生率、骨质疏松药物使用和骨密度检测情况。结果显示3.1%发生脆性骨折,17.6%接受骨质疏松药物处方,9.8%接受骨密度检测,女性各项结局率均高于男性。作者结论指出,尽管骨折风险升高,不足五分之一的帕金森病患者在诊断后一年内接受骨质疏松筛查或治疗,强调需要积极的骨骼健康策略。
要点
- 新诊断帕金森病患者诊断后1年内脆性骨折发生率为3.1%(3.4/100人年)。
- 诊断后1年内17.6%接受骨质疏松药物处方,9.8%接受骨密度检测。
- 女性、年龄≥80岁、既往脆性骨折及更高合并症评分者骨折率更高。
核心结论
- 尽管帕金森病患者骨折风险升高,但诊断后一年内接受骨质疏松筛查或治疗者不足五分之一。
- 作者认为这些发现强调需要积极的骨骼健康策略以预防该高危人群的脆性骨折。
研究设计与样本
- 利用行政数据在加拿大安大略省开展基于人群的队列研究,纳入2008年1月至2023年12月新诊断帕金森病的65岁以上个体。
- 排除后共纳入28,119人,其中女性占39.9%。
- 采用Cox比例风险模型,校正年龄、性别、Charlson合并症评分、既往骨质疏松诊断、脆性骨折史和糖皮质激素使用。
主要发现
- 帕金森病诊断后1年内,3.1%发生脆性骨折(3.4/100人年),17.6%接受骨质疏松药物处方,9.8%接受骨密度检测。
- 所有结局的发生率女性均高于男性。
- 校正分析中,女性、年龄≥80岁、既往脆性骨折和更高合并症评分者骨折率更高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Individuals with Parkinson's disease have an increased fracture risk. We found approximately 3% of individuals newly diagnosed with Parkinson's disease have a fragility fracture in the year following diagnosis, with low rates of screening and treatment for osteoporosis. Education is required to minimize this gap for an at-risk population. PURPOSE: Individuals with Parkinson's disease (PD) have an increased risk of fractures due to increased rates of falls and osteoporosis, yet bone health in PD is often overlooked. This study described fracture rates, use of osteoporosis medications, and bone mineral density (BMD) screening in individuals newly diagnosed with PD. METHODS: Administrative data were used to conduct a population-based cohort study in individuals over 65 years of age, with newly diagnosed PD in Ontario, Canada between January 2008 and December 2023. Descriptive statistics on rates of fracture, use of osteoporosis medication, and BMD testing within the year following diagnosis were reported overall and stratified by sex. Cox proportional hazard models were adjusted for age, sex, Charlson comorbidity score, previous diagnosis of osteoporosis, history of fragility fracture, and use of corticosteroids. RESULTS: After exclusions, 28,119 individuals were included in our cohort, of whom 39.9% were female. Within 1 year of PD diagnosis, 3.1% experienced a fragility fracture (3.4 per 100 person-years), 17.6% received a prescription for an osteoporosis medication, and 9.8% received a BMD test. Rates for all outcomes were greater among females than males. In the adjusted analysis, higher fracture rates were observed in females, those aged ≥ 80 years, with prior fragility fractures, and higher comorbidity scores. CONCLUSION: Despite elevated fracture risk, fewer than one in five individuals with PD received osteoporosis screening or treatment within a year of diagnosis. These findings highlight the need for proactive bone health strategies to prevent fragility fractures in this high-risk population.
引用
- Fleet JL, Carter B, Cadarette SM, et al. Fracture incidence and osteoporosis treatment in Parkinson's disease: a population-based cohort study. Osteoporos Int. 2025. PMID: 41369770. doi:10.1007/s00198-025-07802-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。